Matthew C. Jarvis

University of Minnesota — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

17h-index1.2kcitations41works5.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Epigenetics and DNA Methylation(11), Cancer Genomics and Diagnostics(11), Viral-associated cancers and disorders(7), Polyomavirus and related diseases(7), HIV Research and Treatment(6)

Publications41 total

Redefining high risk multiple myeloma with an APOBEC/Inflammation-based classifier
Leukemia·2024· 5 citedOpen Access
Mutational impact of APOBEC3A and APOBEC3B in a human cell line and comparisons to breast cancer
PLoS Genetics·2023· 45 citedOpen Access
APOBEC3B regulates R-loops and promotes transcription-associated mutagenesis in cancer
Nature Genetics·2023· 70 citedOpen Access
Abstract 5019: Next-generation DYRK1A inhibitors as a new therapeutic approach for the treatment of hematological malignancies
Cancer Research·2023· 4 cited
Supplementary Data from The DNA Cytosine Deaminase APOBEC3B is a Molecular Determinant of Platinum Responsiveness in Clear Cell Ovarian Cancer
2023Open Access
Data from The DNA Cytosine Deaminase APOBEC3B is a Molecular Determinant of Platinum Responsiveness in Clear Cell Ovarian Cancer
2023Open Access
Data from The DNA Cytosine Deaminase APOBEC3B is a Molecular Determinant of Platinum Responsiveness in Clear Cell Ovarian Cancer
2023Open Access
Supplementary Data from The DNA Cytosine Deaminase APOBEC3B is a Molecular Determinant of Platinum Responsiveness in Clear Cell Ovarian Cancer
2023Open Access
Modulation of RNA splicing enhances response to BCL2 inhibition in leukemia
Cancer Cell·2022· 74 citedOpen Access
Primary mucosal melanomas of the head and neck are characterised by overexpression of the <scp>DNA</scp> mutating enzyme <scp>APOBEC3B</scp>
Histopathology·2022· 13 citedOpen Access
An APOBEC/Inflammation-based classifier improves the stratification of multiple myeloma patients and identifies novel risk subgroups
Research Square (Research Square)·2022Open Access
Abstract 925: A genetically engineered mouse model for carcinogenesis by the human enzyme APOBEC3B
Cancer Research·2022
Mutational impact of APOBEC3A and APOBEC3B in a human cell line and comparisons to breast cancer
2022· 13 citedOpen Access
Abstract P5-12-01: Apobec mutation signature in breast cancer explained by combinatorial action of apobec3a and apobec3b
Cancer Research·2022
Identification of Previously Unrecognized Multiple Myeloma Risk Subgroups with a Novel Biological Disease Stratifier
Blood·2021
P-120: Improving the risk stratification of multiple myeloma with a nucleotide editor/inflammation-based scoring system
Clinical Lymphoma Myeloma & Leukemia·2021
R-loop homeostasis and cancer mutagenesis promoted by the DNA cytosine deaminase APOBEC3B
2021· 14 citedOpen Access
OC-0399 Co-occurrence of APOBEC3B and Homologous Recombination Deficiency is Rare in Breast Cancer
Radiotherapy and Oncology·2021
Characterization of the mechanism by which the RB/E2F pathway controls expression of the cancer genomic DNA deaminase APOBEC3B
eLife·2020· 35 citedOpen Access
Author response: Characterization of the mechanism by which the RB/E2F pathway controls expression of the cancer genomic DNA deaminase APOBEC3B
2020· 2 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Reuben S. Harris(31), Prokopios P. Argyris(14), Michael A. Carpenter(11), William L. Brown(11), Artur A. Serebrenik(9), Rachel I. Vogel(8), Jennifer L. McCann(8), Emily K. Law(7), Gabriel J. Starrett(6), Nuri A. Temiz(6), Douglas Marthaler(6), Ham Ching Lam(5), Daniel J. Salamango(5), Margaret R. Brown(5), Martina Bazzaro(5), Britt Erickson(5), Sun Hee Lee(5), Krista M. Goergen(5), Matthew J. Maurer(5), Ethan P. Heinzen(5)